Pancreatic Cancer Research

ResearcherSheng Jing HospitalActive in the last 2 years

Xiaodong Tan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-0862-1306; OpenAlex author ID A5108056359. Sources: OpenAlex.

Their work

Papers
42 (first author 5, last author 26)
Trials
0
Grants
0
Labs led
1
Collaborators
59
Papers, trials and grants by year

2016: 2 papers · 2017: 1 paper · 2018: 8 papers · 2019: 5 papers · 2020: 9 papers · 2021: 3 papers · 2022: 5 papers · 2023: 3 papers · 2024: 2 papers · 2025: 3 papers · 2026: 1 paper

Papers 42

  1. Targeting PAK4 promotes Gemcitabine-induced pyroptosis in pancreatic cancer via NLRP1/caspase-3/GSDME axis. Co-author DOI 10.1038/s42003-026-09538-6↗
  2. New-onset diabetes worsens prognosis of patients with pancreatic ductal adenocarcinoma after R0 resection: A multicenter study. Co-author DOI 10.1016/j.hbpd.2025.04.008↗
  3. VCPIP1 facilitates pancreatic adenocarcinoma progression via Hippo/YAP signaling. Last author DOI 10.1038/s41419-025-07746-2↗
  4. Regulation of the Hippo/YAP signaling pathway in pancreatic cancer by the deubiquitinase POH1 Co-author DOI 10.21203/rs.3.rs-6633989/v1↗
  5. Artificial intelligence to predict T4 stage of pancreatic ductal adenocarcinoma using CT imaging. Co-author DOI 10.1016/j.compbiomed.2024.108125↗
  6. Diagnostic and prognostic value of circulating exosomal glypican-1 in pancreatic cancer: a meta-analysis. Co-author DOI 10.1093/labmed/lmae013↗
  7. Integrated single-cell and bulk RNA sequencing in pancreatic cancer identifies disulfidptosis-associated molecular subtypes and prognostic signature. Last author DOI 10.1038/s41598-023-43036-7↗
  8. Cuproptosis-related LncRNAs signature as biomarker of prognosis and immune infiltration in pancreatic cancer. Last author DOI 10.3389/fgene.2023.1049454↗
  9. Identification of a chemoresistance-related prognostic gene signature by comprehensive analysis and experimental validation in pancreatic cancer. Last author DOI 10.3389/fonc.2023.1132424↗
  10. A combination of circulating tumor cells and CA199 improves the diagnosis of pancreatic cancer. Last author DOI 10.1002/jcla.24341↗
  11. Identification of Prognosis-Related Molecular Subgroups and Construction of a Prognostic Prediction Model Using Immune-Related Genes in Pancreatic Cancer. Last author DOI 10.1155/2022/7117014↗
  12. Exosomal DNAJB11 promotes the development of pancreatic cancer by modulating the EGFR/MAPK pathway. Last author DOI 10.1186/s11658-022-00390-0↗
  13. Exosomal Tenascin-c Induces Proliferation and Invasion of Pancreatic Cancer Cells by WNT Signaling [Retraction]. First author DOI 10.2147/ott.s393902↗
  14. Syntenin Regulated by miR-216b Promotes Cancer Progression in Pancreatic Cancer. Last author DOI 10.3389/fonc.2022.790788↗
  15. ICP-MS and Photothermal Dual-Readout Assay for Ultrasensitive and Point-of-Care Detection of Pancreatic Cancer Exosomes. Co-author DOI 10.1021/acs.analchem.1c02004↗
  16. Identification of Novel Metabolism-Associated Subtypes for Pancreatic Cancer to Establish an Eighteen-Gene Risk Prediction Model. Last author DOI 10.3389/fcell.2021.691161↗
  17. Prognostic Value and Correlation With Tumor Immune Infiltration of a Novel Metabolism-Related Gene Signature in Pancreatic Cancer. Last author DOI 10.3389/fonc.2021.757791↗
  18. Role of exosomal microRNA-125b-5p in conferring the metastatic phenotype among pancreatic cancer cells with different potential of metastasis. First author DOI 10.1016/j.lfs.2020.117857↗
  19. The Ras-ERK1/2 signaling pathway regulates H3K9ac through PCAF to promote the development of pancreatic cancer. Co-author DOI 10.1016/j.lfs.2020.117936↗
  20. HOXB5 promotes proliferation, migration, and invasion of pancreatic cancer cell through the activation of the GSK3β/β-catenin pathway. Last author DOI 10.1097/cad.0000000000000948↗
  21. Integrated analysis identifies a pathway-related competing endogenous RNA network in the progression of pancreatic cancer. Last author DOI 10.1186/s12885-020-07470-4↗
  22. Identification of dissociation factors in pancreatic Cancer using a mass spectrometry-based proteomic approach. Last author DOI 10.1186/s12885-020-6522-3↗
  23. The Ras-ERK signaling pathway regulates acetylated activating transcription factor 2 via p300 in pancreatic cancer cells. Last author DOI 10.21037/atm-20-5880↗
  24. The miR-1224-5p/ELF3 Axis Regulates Malignant Behaviors of Pancreatic Cancer via PI3K/AKT/Notch Signaling Pathways. Last author DOI 10.2147/ott.s248507↗
  25. Multi-omics analysis based on integrated genomics, epigenomics and transcriptomics in pancreatic cancer. Last author DOI 10.2217/epi-2019-0374↗
  26. A Prognostic Prediction Model Developed Based on Four CpG Sites and Weighted Correlation Network Analysis Identified DNAJB1 as a Novel Biomarker for Pancreatic… Last author DOI 10.3389/fonc.2020.01716↗
  27. ITGA6 and RPSA synergistically promote pancreatic cancer invasion and metastasis via PI3K and MAPK signaling pathways. First author DOI 10.1016/j.yexcr.2019.03.022↗
  28. Differential secretome of pancreatic cancer cells in serum-containing conditioned medium reveals CCT8 as a new biomarker of pancreatic cancer invasion and meta… Co-author DOI 10.1186/s12935-019-0980-1↗
  29. Exosomal Tenascin-c induces proliferation and invasion of pancreatic cancer cells by WNT signaling. First author DOI 10.2147/ott.s192218↗
  30. Identification of RE1-Silencing Transcription Factor as a Promoter of Metastasis in Pancreatic Cancer. Last author DOI 10.3389/fonc.2019.00291↗
  31. TSPAN1 upregulates MMP2 to promote pancreatic cancer cell migration and invasion via PLCγ. Last author DOI 10.3892/or.2019.6989↗
  32. ROS mediated EGFR/MEK/ERK/HIF-1α Loop Regulates Glucose metabolism in pancreatic cancer. Last author DOI 10.1016/j.bbrc.2018.04.177↗
  33. Exosomal zinc transporter ZIP4 promotes cancer growth and is a novel diagnostic biomarker for pancreatic cancer. Last author DOI 10.1111/cas.13737↗
  34. Integrated whole genome microarray analysis and immunohistochemical assay identifies COL11A1, GJB2 and CTRL as predictive biomarkers for pancreatic cancer. Last author DOI 10.1186/s12935-018-0669-x↗
  35. Identification of PGAM1 as a putative therapeutic target for pancreatic ductal adenocarcinoma metastasis using quantitative proteomics. Last author DOI 10.2147/ott.s162470↗
  36. Phosphoglycerate Mutase 1 (PGAM1) Promotes Pancreatic Ductal Adenocarcinoma (PDAC) Metastasis by Acting as a Novel Downstream Target of the PI3K/Akt/mTOR Pathw… First author DOI 10.3727/096504018x15166223632406↗
  37. Differential expression profiles of microRNAs in highly and weakly invasive/metastatic pancreatic cancer cells. Co-author DOI 10.3892/ol.2018.9352↗
  38. MicroRNA-221 induces autophagy through suppressing HDAC6 expression and promoting apoptosis in pancreatic cancer. Last author DOI 10.3892/ol.2018.9513↗
  39. IRS-1 regulates proliferation, invasion and metastasis of pancreatic cancer cells through MAPK and PI3K signaling pathways. Last author PMID 31949598↗
  40. UCA1 Regulates the Growth and Metastasis of Pancreatic Cancer by Sponging miR-135a. Last author DOI 10.3727/096504017x14888987683152↗
  41. Quantitative secretomic analysis of pancreatic cancer cells in serum-containing conditioned medium. Co-author DOI 10.1038/srep37606↗
  42. Phosphoproteome Analysis of Invasion and Metastasis-Related Factors in Pancreatic Cancer Cells. Co-author DOI 10.1371/journal.pone.0152280↗

Closest collaborators

The 25 strongest of 59 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Peng Liu · 20 shared papers, 2016–2022 · strength 2.37
  2. Lingming Kong · 9 shared papers, 2019–2022 · strength 1.20
  3. Yunhao Wu · 10 shared papers, 2016–2023 · strength 1.11
  4. Haoyi Jin · 8 shared papers, 2016–2020 · strength 0.81
  5. Xinlu Liu · 6 shared papers, 2018–2022 · strength 0.71
  6. Fuqiang Zu · 4 shared papers, 2020–2022 · strength 0.64
  7. Yifan Yang · 7 shared papers, 2016–2020 · strength 0.60
  8. Keke Liang · 4 shared papers, 2020–2024 · strength 0.56
  9. Zhihao Liu · 2 shared papers, 2025 · strength 0.46
  10. Junliang Chen · 2 shared papers, 2022–2023 · strength 0.44
  11. Xiaobo Zhang · 5 shared papers, 2016–2019 · strength 0.43
  12. Songying Qian · 3 shared papers, 2018–2022 · strength 0.42
  13. Yang Gao · 3 shared papers, 2019–2020 · strength 0.38
  14. Mengwei Wu · 4 shared papers, 2016–2020 · strength 0.35
  15. Hui Chen · 2 shared papers, 2021–2023 · strength 0.34
  16. Xiang Fei · 2 shared papers, 2020–2022 · strength 0.33
  17. Yunhao Wu · 2 shared papers, 2019–2022 · strength 0.33
  18. Feng Li · 1 shared paper, 2026 · strength 0.32
  19. Tianqi Lu · 1 shared paper, 2026 · strength 0.32
  20. Zhongbo Zhang · 1 shared paper, 2026 · strength 0.32
  21. Peng Liu · 2 shared papers, 2021 · strength 0.28
  22. Xiang Fei · 2 shared papers, 2020–2021 · strength 0.28
  23. Jin Shang · 1 shared paper, 2023 · strength 0.26
  24. Mu Li · 2 shared papers, 2020 · strength 0.25
  25. Shaowei Song · 2 shared papers, 2020 · strength 0.25

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.